Immunohistochemical Analysis of WT1 Antigen Expression in Various Solid Cancer Cells

Total Page:16

File Type:pdf, Size:1020Kb

Immunohistochemical Analysis of WT1 Antigen Expression in Various Solid Cancer Cells ANTICANCER RESEARCH 36: 3715-3724 (2016) Immunohistochemical Analysis of WT1 Antigen Expression in Various Solid Cancer Cells KEIKO NAITOH, TAKASHI KAMIGAKI, ERIKO MATSUDA, HIROSHI IBE, SACHIKO OKADA, ERI OGUMA, YOSHIHIRO KINOSHITA, RISHU TAKIMOTO, KAORI MAKITA, SHUN OGASAWARA and SHIGENORI GOTO Seta Clinic, Tokyo, Japan Abstract. For a peptide-pulsed dendritic cell (DC) vaccine cancer vaccines with various cancer antigens in treatment of to work effectively in cancer treatment, it is significant that solid tumors (3-6). For DC-based cancer vaccines, some the target protein is expressed in cancer cells. Wilms’ tumor reports have described insufficient clinical responses despite 1 (WT1) has been identified as a molecular target for the good immunoresponses indicating delayed-type immune cell therapy of cancer. We evaluated the protein hypersensitivity (DTH) (7). Immune check-point inhibitors, expression levels of WT1 in various solid tumors, as well as such as antibodies against programmed cell death protein 1 mucin 1 (MUC1) or major histocompatibility complex (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (MHC) class l molecules. Seven hundred and thirty-eight (CTLA4), are clinically used for patients with advanced or patients whose tissue samples were examined by recurrent melanoma and non-small cell lung cancer to immunohistochemical analysis agreed to undergo DC reverse immune suppression and activate effector T cells (8, vaccine therapy. The positive staining of WT1 in tumor cells 9). Furthermore, the efficacy of immune check-point was observed in 25.3% of patients, with only 8.5% of them inhibitors was reported to correlate with disorders related to showing moderate to strong expression; moreover, WT1 TSAs, oncogenic viral proteins or DNA repair pathway tended to localize in the nucleus and cytoplasm. A positive mutations (10). staining of tumor cells by an anti-MHC class l monoclonal Tumor antigens can be categorized as TSAs, cancer/testis antibody was observed in 98.6% and by an anti-MUC1 (CT) antigens or tumor-associated antigens (TAAs) (11, 12). monoclonal antibody in 76.8% of the patients. In relation to TSAs are abnormal proteins that arise from non-synonymous the application of cancer-specific immunotherapy, these somatic mutations in tumor cells; however, such antigens are findings provide useful information for determining the not expressed in normal cells. CT antigens can be potential efficacy of MUC1- and WT1-targeted therapy. targets as cancer vaccines because their expression is normally restricted to the germ cells of the testis or ovary or Dendritic cell (DC)-based vaccines pulsed with various certain tumor cells (11, 13). TAAs are overexpressed normal tumor-specific antigens (TSAs) have been developed for proteins, such as Wilms’ tumor 1 (WT1) (14, 15) or mucin 1 cancer immunotherapy (1). Our previous data suggest that (MUC1) that regulate growth-promoting functions (16). The immunotherapy with tumor antigen-pulsed immature DCs antigenicity of TAAs was reported to depend on the levels with zoledronate leads to activation of Vγ9γδ T cells and of abnormal expressions (17) because of the lower affinity induction of CD40L on Vγ9γδT cells (2). The activated of the T cell receptor (TCR) against TAAs than of TCR Vγ9γδT cells secret T helper (Th)1-cytokines, such as against TSAs (18). interferon (IFN)-γ, and enhance the expansion of tumor For DC vaccines loaded with various TAAs peptides, their antigen-specific CD8+ cells by tumor antigen-pulsed phase I/IIa clinical trial for immunotherapy was carried out immature DCs. We utilized zoledronate-pulsed DCs as in elderly patients with acute myeloid leukemia (AML), using pulsed DCs with a modified WT1 peptide and zoledronate (19). In that trial, three human leukocyte antigen (HLA)- A2402-positive elderly patients with AML were enrolled. The Correspondence to: Keiko Naitoh, Senior Chief Researcher of induction of immunoresponses to the WT1 peptide detected Clinical Research Center, Seta Clinic, 2-1-45 Kanda-surugadai, as DTH was indicated in two of the three patients, with a Chiyoda, Tokyo 101-0062, Japan. Tel: +81 352445751, Fax: +81 transient decrease in the number of leukemic cells being 332190750, e-mail: [email protected] observed in these two patients. Unfortunately, a rapid Key Words: Immune cell therapy, immunohistochemistry, WT1, expansion of leukemic cells was observed in the patient dendritic cell vaccine therapy. showing no immunoresponses to the WT1-specific peptide 0250-7005/2016 $2.00+.40 3715 ANTICANCER RESEARCH 36: 3715-3724 (2016) after the third vaccination. Recently, we studied a DC vaccine Evaluation method. The relative ratio (proportion) and positive pulsed with zoledronate and an overlapping pool of peptides reaction strength (i.e., staining intensity) were determined to analyze derived from the full length of WT1 for patients with WT1- antigen expression. The level and distribution of expression were subjectively estimated and positive reaction strength was described expressing solid tumors as both CD8+ cytotoxic T as -, +, ++ and +++ (Table ll). lymphocytes (CTLs) and CD4+ T-helper cells against WT1 can be potentially induced without HLA restriction. However, in order to be recognized by CTLs with low-affinity TCRs, it Results is essential that a sufficient amount of TAAs, such as WT1 or MUC1, should be presented by major histocompatibility Immunohistochemical findings of WT1, MUC1 and MHC complex (MHC) class I on tumor cells (20). class I protein expressions in tumor cells. We studied WT1 In the present study, we examined the protein expression protein expression in various solid tumors by levels of WT1 in various solid tumors, as well as MUC1 or immunohistochemical staining using monoclonal antibodies MHC class I molecules by immunohistochemical analysis. against WT1, MUC1 and MHC class I molecules. The We also analyzed the organ and histopathological profiles of results of the immunohistochemical staining of WT1 WT1 protein expression in various malignancies classified expressed in various solid tumors are shown in Figure 1. For on the basis of ICD10 and ICD-O-3. malignant pleural mesothelioma, a strong expression of the WT1 protein was observed in the nucleus of tumor cells Materials and Methods (Figure 1A). A weak expression of WT1 protein was observed only in the cytoplasm of cancer cells and in both Patients’ background. Between October 2007 and September 2014, the nucleus and cytoplasm of breast cancer and malignant tumor samples were obtained intraoperatively or by biopsy from pleural mesothelioma cells, respectively (Figure 1B and C). 738 patients who provided their informed consent to four facilities of the Seta Clinic Group. The patients agreed to undergo DC It is shown in Figure 1D that no WT1 protein expression was vaccine therapy and their tissue samples were examined by found in one patient with adenocarcinoma of the pancreas. immunohistochemical analysis for the expression levels of WT1, Immunohistochemical staining showed MUC1 expression at MUC1 and MHC class I molecules. The mean age of the 738 the luminal and/or apical site of cancer cells (Figure 2A and patients was 58.6 years (range=6-87) and the male-to-female ratio B). MHC class I molecules were expressed in most of the was 1:1.10 (352:386). In this study, 55 cancer types (ICD-10) and solid tumors; however, loss or down-regulation of the 24 histological types (ICD-O-3M) were included (Table I). expression of MHC class I molecules was observed in few Specimens. A total of 738 specimens were examined, comprising of tumors (Figure 2C and D). 72 stomach cancers, 68 colon cancers, 47 rectum cancers, 63 pancreas cancers, 120 lung cancers, 48 breast cancers and 63 Analysis of WT1, MUC1 and MHC class I protein expression ovarian cancers. The remaining tumor types are summarized in in various tumors classified on the basis of ICD10. We Table I. The prepared paraffin-embedded or formalin-fixed tissues categorized the WT1 expression patterns in tumors classified were examined at Tokyo Central Pathology Laboratory Company. on the basis of ICD10 and ICD-O-3. Additionally, we also The histological diagnosis of each tumor was confirmed on the basis studied the expression patterns of MUC1, as one of the of hematoxylin and eosin staining results and the pathological reports provided by each medical facility. TAAs, and MHC class I molecules, as antigen presentation- associated molecules in various tumors. The expression Immunohistochemistry. A mouse monoclonal anti-human WT1 levels of WT1, MUC1 and MHC class I in various tumors protein antibody (immunogen:human WT1 protein consisting of N- classified on the basis of ICD10 are shown in Table III. The terminal amino acids 1-181, clone 6F-H2; Dako, Glostrup, expression of WT1 substantially differed depending on the Denmark), an anti-MUC-1 glycoprotein mouse monoclonal antibody tumor site, classified on the basis of ICD10. On the other (Novacastra Laboratories Ltd., Newcastle, UK) and an anti-HLA hand, MUC1 expression was observed in most solid tumors. class I-A, B, C mouse monoclonal antibody (Hokudo Co., Ltd., Hokkaido, Japan) were used for the detection of WT1, MUC1 and For malignant mesothelioma, WT1 expression was found in MHC class l antigens, respectively. all tumors. Additionally, a high frequency of WT1 expression was shown (39.3%; 46/117) for the malignancies of female WT1 immunohistochemical staining method. The mouse monoclonal genital organs (ICD10; C52-C59), including cancers of the anti-WT1 antibody (clone 6F-H2; Dako), an enzyme antibody ovary (52.4%; 33/63). The frequency of WT1 expression was LSAB method (labeled streptavidin-biotin) (21), and a Ventana also relatively high in cancers of the bile duct (C23-24, Benchmark XT (Ventana Medical Systems, Inc., Arizona, USA) 41.2%; 7/17), lung (C34, 35.0%; 42/120), breast (C50, device were used for the immunohistochemical staining. Tissue sections were prepared as follows: enzyme and heat treatment for 8 25.0%; 12/48) and prostate (C61, 28.6%; 4/14).
Recommended publications
  • Bladder Cancer Early Detection, Diagnosis, and Staging Detection and Diagnosis
    cancer.org | 1.800.227.2345 Bladder Cancer Early Detection, Diagnosis, and Staging Detection and Diagnosis Finding cancer early, when it's small and hasn't spread, often allows for more treatment options. Some early cancers may have signs and symptoms that can be noticed, but that's not always the case. ● Can Bladder Cancer Be Found Early? ● Bladder Cancer Signs and Symptoms ● Tests for Bladder Cancer Stages and Outlook (Prognosis) After a cancer diagnosis, staging provides important information about the extent (amount) of cancer in the body and the likely response to treatment. ● Bladder Cancer Stages ● Survival Rates for Bladder Cancer Questions to Ask About Bladder Cancer Here are some questions you can ask your cancer care team to help you better understand your cancer diagnosis and treatment options. ● Questions To Ask About Bladder Cancer 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 Can Bladder Cancer Be Found Early? Bladder cancer can sometimes be found early -- when it's small and hasn't spread beyond the bladder. Finding it early improves your chances that treatment will work. Screening for bladder cancer Screening is the use of tests or exams to look for a disease in people who have no symptoms. At this time, no major professional organizations recommend routine screening of the general public for bladder cancer. This is because no screening test has been shown to lower the risk of dying from bladder cancer in people who are at average risk. Some providers may recommend bladder cancer tests for people at very high risk, such as: ● People who had bladder cancer before ● People who had certain birth defects of the bladder ● People exposed to certain chemicals at work Tests that might be used to look for bladder cancer Tests for bladder cancer look for different substances and/or cancer cells in the urine.
    [Show full text]
  • Wt1) – an Effector in Leukemogenesis?
    WILMS’ TUMOUR GENE 1 PROTEIN (WT1) – AN EFFECTOR IN LEUKEMOGENESIS? Vidovic, Karina 2010 Link to publication Citation for published version (APA): Vidovic, K. (2010). WILMS’ TUMOUR GENE 1 PROTEIN (WT1) – AN EFFECTOR IN LEUKEMOGENESIS?. Lund University: Faculty of Medicine. Total number of authors: 1 General rights Unless other specific re-use rights are stated the following general rights apply: Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal Read more about Creative commons licenses: https://creativecommons.org/licenses/ Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. LUND UNIVERSITY PO Box 117 221 00 Lund +46 46-222 00 00 Download date: 07. Oct. 2021 Division of Hematology and Transfusion Medicine Lund University, Lund, Sweden WILMS’ TUMOUR GENE 1 PROTEIN (WT1) – AN EFFECTOR IN LEUKEMOGENESIS? Karina Vidovic Thesis 2010 Contact adress Karina Vidovic Division of Hematology and Transfusion Medicine BMC, C14 Klinikgatan 28 SE- 221 84 Lund Sweden Phone +46 46 222 07 30 e-mail: [email protected] ISBN 978-91-86443-99-3 ! Karina Vidovic Printed by Media-Tryck, Lund, Sweden 2 ”The journey of a thousand miles begins with one step” Lao Tzu (Chinese taoist), 600-531 BC 3 4 LIST OF PAPERS This thesis is based on the following papers, referred to in the text by their Roman numerals I.
    [Show full text]
  • An Integrated Genome Screen Identifies the Wnt Signaling Pathway As a Major Target of WT1
    An integrated genome screen identifies the Wnt signaling pathway as a major target of WT1 Marianne K.-H. Kima,b, Thomas J. McGarryc, Pilib O´ Broind, Jared M. Flatowb, Aaron A.-J. Goldend, and Jonathan D. Lichta,b,1 aDivision of Hematology/Oncology and cFeinberg Cardiovascular Research Institute, Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611; bRobert H. Lurie Cancer Center, Northwestern University, Chicago, IL 60611; and dDepartment of Information Technology, National University of Ireland, Galway, Republic of Ireland Edited by Peter K. Vogt, The Scripps Research Institute, La Jolla, CA, and approved May 18, 2009 (received for review February 12, 2009) WT1, a critical regulator of kidney development, is a tumor suppressor control. A first generation of in vitro cotransfection and DNA for nephroblastoma but in some contexts functions as an oncogene. binding assays have given way to more biologically relevant exper- A limited number of direct transcriptional targets of WT1 have been iments where manipulation of WT1 levels has been accompanied identified to explain its complex roles in tumorigenesis and organo- by examination of candidate or global gene expression. Classes of genesis. In this study we performed genome-wide screening for direct WT1 targets thus identified consist of inducers of differentiation, WT1 targets, using a combination of ChIP–ChIP and expression arrays. regulators of cell growth and modulators of cell death. WT1 target Promoter regions bound by WT1 were highly G-rich and resembled genes include CDKN1A (22), a negative regulator of the cell cycle; the sites for a number of other widely expressed transcription factors AREG (23), a facilitator of kidney differentiation; WNT4 (24), a such as SP1, MAZ, and ZNF219.
    [Show full text]
  • Package Insert
    BCG LIVE (FOR INTRAVESICAL USE) TICE® BCG WARNING TICE® BCG contains live, attenuated mycobacteria. Because of the potential risk for transmission, it should be prepared, handled, and disposed of as a biohazard material (see PRECAUTIONS and DOSAGE AND ADMINISTRATION). BCG infections have been reported in health care workers, primarily from exposures resulting from accidental needle sticks or skin lacerations during the preparation of BCG for administration. Nosocomial infections have been reported in patients receiving parenteral drugs that were prepared in areas in which BCG was reconstituted. BCG is capable of dissemination when administered by the intravesical route, and serious infections, including fatal infections, have been reported in patients receiving intravesical BCG (see WARNINGS, PRECAUTIONS, and ADVERSE REACTIONS). DESCRIPTION TICE® BCG for intravesical use, is an attenuated, live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis.1 The TICE® strain was developed at the University of Illinois from a strain originated at the Pasteur Institute. The medium in which the BCG organism is grown for preparation of the freeze-dried cake is composed of the following ingredients: glycerin, asparagine, citric acid, potassium phosphate, magnesium sulfate, and iron ammonium citrate. The final preparation prior to freeze drying also contains lactose. The freeze-dried BCG preparation is delivered in glass vials, each containing 1 to 8 x 108 colony forming units (CFU) of TICE® BCG which is equivalent to approximately 50 mg wet weight. Determination of in- vitro potency is achieved through colony counts derived from a serial dilution assay. A single dose consists of 1 reconstituted vial (see DOSAGE AND ADMINISTRATION).
    [Show full text]
  • Primary Melanoma of the Bladder at Puerperium
    ISSN: 2469-5742 Rubio et al. Int Arch Urol Complic 2020, 6:073 DOI: 10.23937/2469-5742/1510073 Volume 6 | Issue 1 International Archives of Open Access Urology and Complications CASE REPORT Primary Melanoma of the Bladder at Puerperium: Case Report Rubio Galisteo JM1*, Gomez Gomez E1, Valero Rosa J1, Salguero Segura J1, Pineda Reyes B2, Gonzalez T3, Barbudo Merino J4, Ruiz Garcia JM1 and Requena Tapia MJ1 1Urology Department, Hospital Universitario Reina Sofia, Spain 2Ginecology Department, Hospital Universitario Reina Sofia, Spain 3 Check for Pathological Anatomy Department, Hospital Universitario Reina Sofia, Spain updates 4Emergency Department, Hospital Universitario Reina Sofia, Spain *Corresponding author: Rubio Galisteo JM, Urology Department, Hospital Universitario Reina Sofía, Av Menendez Pidal S/N, UGC Urología, Córdoba, CP: 14004, Spain, Tel: +3460-004-5566 of urinary bladder in a 39-years-old postpartum wom- Abstract an. Primary malignant melanoma of the urinary bladder is a sporadic disease and very little described in the literature. Case Presentation A 39-years-old female at the end of her pregnancy without previous history of skin disease was presented with hema- A healthy 39-years-old female is presented at the turia after cesarean and with constitutional syndrome. After end of her first pregnancy. The patient gives a history of the study, the patient was diagnosed with metastatic blad- 10 kg lost at the last months, and urinary tract infection der melanoma. Other locations of primary injury were ruled out. The patient died a month and a half after the diagnosis. treated with antibiotics with a urine culture positive to E.
    [Show full text]
  • Clinical Radiation Oncology Review
    Clinical Radiation Oncology Review Daniel M. Trifiletti University of Virginia Disclaimer: The following is meant to serve as a brief review of information in preparation for board examinations in Radiation Oncology and allow for an open-access, printable, updatable resource for trainees. Recommendations are briefly summarized, vary by institution, and there may be errors. NCCN guidelines are taken from 2014 and may be out-dated. This should be taken into consideration when reading. 1 Table of Contents 1) Pediatrics 6) Gastrointestinal a) Rhabdomyosarcoma a) Esophageal Cancer b) Ewings Sarcoma b) Gastric Cancer c) Wilms Tumor c) Pancreatic Cancer d) Neuroblastoma d) Hepatocellular Carcinoma e) Retinoblastoma e) Colorectal cancer f) Medulloblastoma f) Anal Cancer g) Epndymoma h) Germ cell, Non-Germ cell tumors, Pineal tumors 7) Genitourinary i) Craniopharyngioma a) Prostate Cancer j) Brainstem Glioma i) Low Risk Prostate Cancer & Brachytherapy ii) Intermediate/High Risk Prostate Cancer 2) Central Nervous System iii) Adjuvant/Salvage & Metastatic Prostate Cancer a) Low Grade Glioma b) Bladder Cancer b) High Grade Glioma c) Renal Cell Cancer c) Primary CNS lymphoma d) Urethral Cancer d) Meningioma e) Testicular Cancer e) Pituitary Tumor f) Penile Cancer 3) Head and Neck 8) Gynecologic a) Ocular Melanoma a) Cervical Cancer b) Nasopharyngeal Cancer b) Endometrial Cancer c) Paranasal Sinus Cancer c) Uterine Sarcoma d) Oral Cavity Cancer d) Vulvar Cancer e) Oropharyngeal Cancer e) Vaginal Cancer f) Salivary Gland Cancer f) Ovarian Cancer & Fallopian
    [Show full text]
  • Renal Transitional Cell Carcinoma: Case Report from the Regional Hospital Buea, Cameroon and Review of Literature Enow Orock GE1*, Eyongeta DE2 and Weledji PE3
    Enow Orock, Int J Surg Res Pract 2014, 1:1 International Journal of ISSN: 2378-3397 Surgery Research and Practice Case Report : Open Access Renal Transitional Cell Carcinoma: Case report from the Regional Hospital Buea, Cameroon and Review of Literature Enow Orock GE1*, Eyongeta DE2 and Weledji PE3 1Pathology Unit, Regional Hospital Buea, Cameroon 2Urology Unit, Regional Hospital Limbe, Cameroon 3Surgical Unit, Regional Hospital Buea, Cameroon *Corresponding author: Enow Orock George, Pathology Unit, Regional Hospital Buea, South West Region, Cameroon, Tel: (237) 77716045, E-mail: [email protected] Abstract United States in 2009. Primary renal pelvis and ureteric malignancies, on the other hand, are much less common with an estimated 2,270 Although transitional cell carcinoma is the most common tumour of the renal pelvis, we report the first histologically-confirmed case in cases diagnosed and 790 deaths in 2009 [6]. Worldwide statistics our service in a period of about twenty years. The patient is a mid- vary with the highest incidence found in the Balkans where urothelial aged female African, with no apparent risks for the disease. She cancers account for 40% of all renal cancers and are bilateral in 10% presented with the classical sign of the disease (hematuria) and of cases [7]. We report a first histologically-confirmed case of renal was treated by nephrouretectomy for a pT3N0MX grade II renal pelvic transitional cell carcinoma in 20 years of practice in a mid-aged pelvic tumour. She is reporting well one year after surgery. The case African woman. highlights not only the peculiar diagnosis but also illustrates the diagnostic and management challenges posed by this and similar Case Report diseases in a low- resource setting like ours.
    [Show full text]
  • Urinary Bladder Neoplasia
    Canine Urinary Tract Neoplasia Phyllis C Glawe DVM, MS The principal organs of the urinary tract are the kidneys, ureters, urinary bladder and urethra. The urinary bladder and urethra are the most commonly affected by cancer in the dog and the majority of cancers in these locations are malignant. The most common type of cancer is Transitional Cell Carcinoma (TCC). This handout reviews the facts about clinical symptoms, diagnosis and treatment of urinary tract cancer in the dog. Clinical Features More common in female dogs, urinary bladder and urethral cancer are typically associated with advanced age (9-10 years). Frequent urination, blood in the urine, and straining to urinate are typical symptoms. These signs are also similar to those of urinary tract infections, thus a cancer diagnosis can be missed early in the course of the disease. If the flow of urine is obstructed, abdominal pain, vomiting, depression and loss of appetite can occur. More rarely, dogs can present with back pain and weakness of the hind limbs due to metastases (spread) of the cancer to the spine and lymph nodes. Diagnosis Abdominal radiographs and abdominal ultrasound can be utilized to detect cancer in the lower urinary tract. Abdominal ultrasound is particularly helpful to assess whether other organs in the abdomen region are affected, such as the kidneys and ureters. Hydronephrosis and hydroureter are terms describing a back-up of urine flow due to the obstructive effects of a tumor. Regional lymph node enlargement and possible prostate enlargement in male dogs can be assessed quickly and accurately with ultrasound. Urine analysis is not very helpful as a diagnostic tool in most cases.
    [Show full text]
  • Primary Urethral Carcinoma
    EAU Guidelines on Primary Urethral Carcinoma G. Gakis, J.A. Witjes, E. Compérat, N.C. Cowan, V. Hernàndez, T. Lebret, A. Lorch, M.J. Ribal, A.G. van der Heijden Guidelines Associates: M. Bruins, E. Linares Espinós, M. Rouanne, Y. Neuzillet, E. Veskimäe © European Association of Urology 2017 TABLE OF CONTENTS PAGE 1. INTRODUCTION 3 1.1 Aims and scope 3 1.2 Panel composition 3 1.3 Publication history and summary of changes 3 1.3.1 Summary of changes 3 2. METHODS 3 2.1 Data identification 3 2.2 Review 3 2.3 Future goals 4 3. EPIDEMIOLOGY, AETIOLOGY AND PATHOLOGY 4 3.1 Epidemiology 4 3.2 Aetiology 4 3.3 Histopathology 4 4. STAGING AND CLASSIFICATION SYSTEMS 5 4.1 Tumour, Node, Metastasis (TNM) staging system 5 4.2 Tumour grade 5 5. DIAGNOSTIC EVALUATION AND STAGING 6 5.1 History 6 5.2 Clinical examination 6 5.3 Urinary cytology 6 5.4 Diagnostic urethrocystoscopy and biopsy 6 5.5 Radiological imaging 7 5.6 Regional lymph nodes 7 6. PROGNOSIS 7 6.1 Long-term survival after primary urethral carcinoma 7 6.2 Predictors of survival in primary urethral carcinoma 7 7. DISEASE MANAGEMENT 8 7.1 Treatment of localised primary urethral carcinoma in males 8 7.2 Treatment of localised urethral carcinoma in females 8 7.2.1 Urethrectomy and urethra-sparing surgery 8 7.2.2 Radiotherapy 8 7.3 Multimodal treatment in advanced urethral carcinoma in both genders 9 7.3.1 Preoperative platinum-based chemotherapy 9 7.3.2 Preoperative chemoradiotherapy in locally advanced squamous cell carcinoma of the urethra 9 7.4 Treatment of urothelial carcinoma of the prostate 9 8.
    [Show full text]
  • Wilms' Tumor Gene 1 in Different Types of Cancer
    UMEÅ UNIVERSITY MEDICAL DISSERTATIONS New Series No.1717 ISSN 0346-6612 ISBN 978-91-7601-263-5 Wilms’ tumor gene 1 in different types of cancer Xingru Li Department of Medical Biosciences, Clinical Chemistry Umeå University, Sweden Umeå 2015 Copyright © 2015 Xingru Li ISBN: 978-91-7601-263-5 ISSN: 0346-6612 Printed by: Print & Media Umeå, Sweden, 2015 To my family Table of Contents Abstract .......................................................................................................... 1 Original Articles ............................................................................................. 2 Abbreviations ................................................................................................. 3 Introduction .................................................................................................... 4 WT1 (Wilms’ tumor gene 1) ...................................................................... 4 Structure of WT1 ..................................................................................... 4 WT1, the transcription factor ................................................................. 5 WT1 and its interacting partners ............................................................ 5 WT1 function .......................................................................................... 8 The tumor suppressor ........................................................................ 8 An oncogene ...................................................................................... 8 Mutations and
    [Show full text]
  • Urothelial Carcinoma of Bladder and Upper Tract
    Urothelial Carcinoma of Bladder and Upper Tract Page 1 of 18 Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women. Note: Consider Clinical Trials as treatment options for eligible patients. CLINICAL INITIAL INITIAL INITIAL SCREEN PRESENTATION EVALUATION DIAGNOSIS STAGING Negative for Treat as indicated3 bladder cancer Less than T2 See Page 2-3 ● Hematuria ● History and physical ● Transurethral resection (TUR) ● Recurrent unexplained 1 ● Office cystoscopy ● Exam under anesthesia (EUA) urinary tract infection Positive for ● Imaging: CT urogram or ● Consider single dose peri- ● Other unexplained bladder cancer 4 intravenous urogram (IVU) operative chemotherapy lower urinary tract 2 ● Lifestyle risk assessment instillation symptoms T2-4 See Page 4 (muscle invasion) Positive for See Page 6 upper tract tumor 1 Consider urinary cytology or other MD Anderson approved genitourinary biomarkers 2 See Physical Activity, Nutrition, and Tobacco Cessation algorithms; ongoing reassessment of lifestyle risks should be a part of routine clinical practice 3 If persistant microhematuria, recommend repeat of history and physical, office cystoscopy, imaging (CT urogram or IVU) in 2-3 years 4 Refer to Principles of Intravesical Treatment on Page 8 Department of Clinical Effectiveness V9 Approved by The Executive Committee of the Medical Staff on 07/21/2020 Urothelial Carcinoma of Bladder and Upper Tract Page 2 of 18 Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information.
    [Show full text]
  • Sarcomatoid Urothelial Carcinoma Arising in the Female Urethral Diverticulum
    Journal of Pathology and Translational Medicine 2021; 55: 298-302 https://doi.org/10.4132/jptm.2021.04.23 CASE STUDY Sarcomatoid urothelial carcinoma arising in the female urethral diverticulum Heae Surng Park Department of Pathology, Ewha Womans University Seoul Hospital, Seoul, Korea A sarcomatoid variant of urothelial carcinoma in the female urethral diverticulum has not been reported previously. A 66-year-old woman suffering from dysuria presented with a huge urethral mass invading the urinary bladder and vagina. Histopathological examination of the resected specimen revealed predominantly undifferentiated pleomorphic sarcoma with sclerosis. Only a small portion of conven- tional urothelial carcinoma was identified around the urethral diverticulum, which contained glandular epithelium and villous adenoma. The patient showed rapid systemic recurrence and resistance to immune checkpoint inhibitor therapy despite high expression of pro- grammed cell death ligand-1. We report the first case of urethral diverticular carcinoma with sarcomatoid features. Key Words: Sarcomatoid carcinoma; Urothelial carcinoma; Urethral diverticulum Received: March 9, 2021 Revised: April 16, 2021 Accepted: April 23, 2021 Corresponding Author: Heae Surng Park, MD, PhD, Department of Pathology, Ewha Womans University Seoul Hospital, Ewha Womans University College of Medicine, 260 Gonghang-daero, Gangseo-gu, Seoul 07804, Korea Tel: +82-2-6986-5253, Fax: +82-2-6986-3423, E-mail: [email protected] Urethral diverticular carcinoma (UDC) is extremely rare; the urinary bladder, and vagina with enlarged lymph nodes at both most common histological subtype is adenocarcinoma [1,2]. femoral, both inguinal, and both internal and external iliac areas Sarcomatoid urothelial carcinoma (UC) is also unusual. Due to (Fig. 1B).
    [Show full text]